Lytix Biopharma AS (LYTIX) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.969x

Based on the latest financial reports, Lytix Biopharma AS (LYTIX) has a cash flow conversion efficiency ratio of -0.969x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-59.85 Million ≈ $-6.30 Million USD) by net assets (Nkr61.75 Million ≈ $6.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LYTIX net asset quality score to measure how much of total assets are equity-financed.

Lytix Biopharma AS - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Lytix Biopharma AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Lytix Biopharma AS investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Lytix Biopharma AS Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lytix Biopharma AS ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Poalim Ibi TA:PIU	0.048x
WINS Co. Ltd KQ:136540	0.022x
MANUKA RESOURCES LTD F:6M0A	N/A
Unifi Inc NYSE:UFI	0.035x
Central Plains Bancshares, Inc. Common Stock NASDAQ:CPBI	0.026x
Great Elm Capital Corp NASDAQ:GECC	0.219x
Shanghai Shibei Hi-Tech Co Ltd B SHG:900902	-0.011x
Brand Engagement Network Inc NASDAQ:BNAI	-0.512x

Annual Cash Flow Conversion Efficiency for Lytix Biopharma AS (2017–2025)

The table below shows the annual cash flow conversion efficiency of Lytix Biopharma AS from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Lytix Biopharma AS (LYTIX) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Nkr61.75 Million ≈ $6.50 Million	Nkr-59.85 Million ≈ $-6.30 Million	-0.969x	-48.60%
2024-12-31	Nkr107.89 Million ≈ $11.35 Million	Nkr-70.37 Million ≈ $-7.41 Million	-0.652x	+65.12%
2023-12-31	Nkr51.32 Million ≈ $5.40 Million	Nkr-95.97 Million ≈ $-10.10 Million	-1.870x	-385.00%
2022-12-31	Nkr135.13 Million ≈ $14.22 Million	Nkr-52.10 Million ≈ $-5.48 Million	-0.386x	-62.86%
2021-12-31	Nkr189.62 Million ≈ $19.95 Million	Nkr-44.90 Million ≈ $-4.72 Million	-0.237x	+80.66%
2020-12-31	Nkr19.89 Million ≈ $2.09 Million	Nkr-24.35 Million ≈ $-2.56 Million	-1.224x	+54.85%
2019-12-31	Nkr13.58 Million ≈ $1.43 Million	Nkr-36.82 Million ≈ $-3.87 Million	-2.711x	-53.27%
2018-12-31	Nkr41.05 Million ≈ $4.32 Million	Nkr-72.62 Million ≈ $-7.64 Million	-1.769x	+70.06%
2017-12-31	Nkr11.79 Million ≈ $1.24 Million	Nkr-69.67 Million ≈ $-7.33 Million	-5.909x	--

About Lytix Biopharma AS

OL:LYTIX Norway Biotechnology

Market Cap

$73.64 Million

Nkr699.79 Million NOK

Market Cap Rank

#20354 Global

#179 in Norway

Share Price

Nkr9.10

Change (1 day)

+1.34%

52-Week Range

Nkr6.90 - Nkr11.50

All Time High

Nkr18.60